Details for Patent: 7,329,672

Title:	2,4-pyrimidinediamine compounds and their uses
Abstract:	The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s):	Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald (Hillsborough, CA), Molineaux; Susan (San Mateo, CA), Holland; Sacha J. (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Menlo Park, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (Burlingame, CA), Li; Hui (Millbrae, CA), Rossi; Alexander B. (San Francisco, CA)
Assignee:	Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Filing Date:	Jun 08, 2005
Application Number:	11/149,105
Claims:	1. N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyle- neoxyphenyl]-2,4-pyrimidinediamine or salt, hydrate, solvate and/or N-oxide thereof. 2. A pharmaceutical composition comprising N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneo- xyphenyl]-2,4-pyrimidinediamine and/or a salt, hydrate, solvate or N-oxide thereof, and a pharmaceutically acceptable carrier, diluent and/or excipient. 3. The composition of claim 2 which comprises a pharmaceutically acceptable salt of N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneo- xyphenyl]-2,4-pyrimidinediamine or a hydrate, solvate and/or N -oxide thereof. 4. The composition of claim 2 in which the salt is a hydrochloride salt, a hydrogen sulfate salt, a sulfate salt, a phosphate salt, an alkane sulfonate salt, a methane sulfonate salt, an ethane sulfonate salt or a p-toluene sulfonate salt. 5. A method of inhibiting IgG-induced or IgE-induced degranulation of a cell, comprising contacting a cell capable of undergoing IgG-induced or IgE-induced degranulation with an amount of N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneo- xyphenyl]-2,4-pyrimidinediamine and/or a salt, hydrate, solvate and/or N-oxide thereof, effective to inhibit IgG-induced or IgE-induced degranulation of the cell. 6. The method of claim 5 in which the cell is a human mast, basophil cell, neutrophil or eosinophil cell. 7. A method of inhibiting IgG-induced or IgE-induced mast or basophil cell degranulation in an animal, comprising administering to the animal an amount of N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneo- xyphenyl]-2,4-pyrimidinediamine and/or a salt, hydrate, solvate and/or N-oxide thereof, effective to inhibit IgG-induced or IgE-induced mast or basophil cell degranulation. 8. The method of claim 7 in which the animal is a human. 9. The method of claim 8 in which human is suffering from a disease selected from allergic diseases, low grade scarring, diseases associated with tissue destruction, diseases associated with tissue inflammation, and inflammation. 10. The method of claim 9 in which the allergic disease is selected from conjunctivitis, rhinitis, asthma, atopic dermatitis and food allergies. 11. The method of claim 9 in which the low grade scarring is selected from scieroderma, increased fibrosis, keloids, post-surgical scars, pulmonary fibrosis, vascular spasms, migraine, reperfusion injury and post myocardial infarction. 12. The method of claim 9 in which the disease associated with tissue destruction is selected from COPD, cardiobronchitis and post myocardial infarction. 13. The method of claim 9 in which the disease associated with tissue inflammation is selected from irritable bowel, spastic colon and inflammatory colon disease. 14. A method of inhibiting a Syk kinase, comprising the step of contacting a Syk kinase or an active fragment thereof with an effective amount of N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonyl- methyleneoxyphenyl]-2,4-pyrimidinediamine and/or a salt, hydrate, solvate and/or N-oxide thereof. 15. The method of claim 14 which is practiced in vitro with an isolated or recombinant Syk kinase. 16. The method of claim 14 which is practiced in vitro with a cell or cell population that expresses an endogenous or recombinant Syk kinase. 17. The method of claim 14 which is practiced in vivo. 18. A method of inhibiting a Syk kinase in an animal, comprising the step of administering to the animal an amount of N4-(1,4-Benzoxazin-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneo- xyphenyl]-2,4-pyrimidinediamine or a salt, hydrate, solvate and/or N-oxide thereof, effective to inhibit a Syk kinase. 19. The method of claim 18 in which the animal is a human.